Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$9.07 -1.39%

-$0.26 today

Market cap
$775.03M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.26M

Average 1.02M

GLUE Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Monte Rosa Therapeutics, Inc.NASDAQ: GLUE

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $2.03M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $2.03M.

Context

  • Cost of revenue amounted to 6.8% of revenue in FY2025, down 4.0 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $2.03M or moves back toward the trailing-twelve-month quarterly average of $507.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.03M— QoQ
Last fiscal yearDec 2025
$8.36M+2.9% YoY
LTMMar 2026
$2.03M-1.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+2.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
8.36M USD
Year-over-year change
+2.9%

Cost of Revenue vs competitors

How GLUE compares with its peers on the latest reported figures

  • GLUE's LTM Mar 2026 cost of revenue of $2.03M is the 3rd highest of the 4 companies compared; the peer median is $2.3M.
  • Its year-over-year change of -1.5% is the 2nd highest of 4, against a peer median of -56.9%.
  • Cost of revenue amounts to 4.7% of revenue for GLUE, versus a peer median of 5.2%.
GLUE Competitors Peer median
Cost of Revenue for GLUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M -56.9%-53.2%13.5%
ARVNArvinas, Inc.LTM Mar 2026$2.3M +35.3%—2.6%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$2.03M -1.5%—4.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$1.8M -69.3%—5.2%
Peer median (excluding GLUE) $2.3M-56.9%-53.2%5.2%

Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00075.62M123.67M
Cost of Revenue006.22M8.12M8.36M
Gross Profit00(6.22M)67.5M115.32M
Gross Margin———89.3%93.2%
Research & Development57.16M85.06M105.05M121.56M141.5M
Selling, General & Admin15.73M27.32M32.04M35.17M36.38M
Operating Expenses72.88M112.38M137.09M148.61M169.52M
Depreciation & Amortization2.13M3.75M6.22M8.12M8.36M
EBITDA(71.83M)(100.99M)(128.79M)(62.01M)(31.37M)
EBITDA Margin———-82.0%-25.4%
Operating Income(72.88M)(112.38M)(143.31M)(81.11M)(54.21M)
Operating Margin———-107.3%-43.8%
Interest Income46K3.76M9.33M10.57M12.94M
Interest Expense03.76M000
Other Income / Expenses(1.08M)3.88M8.3M10.98M14.49M
Income Before Tax(73.96M)(108.5M)(135.01M)(70.13M)(39.72M)
Pre-Tax Margin———-92.7%-32.1%
Income Tax Expense00338K2.57M(1.1M)
Net Income(73.96M)(108.5M)(135.35M)(72.7M)(38.63M)
Net Margin———-96.1%-31.2%
EPS (Basic)(1.59)(2.30)(2.63)(0.98)(0.46)
EPS (Diluted)(1.59)(2.30)(2.63)(0.98)(0.46)
Weighted Avg Shares46.54M47.23M51.4M73.91M83.07M
Weighted Avg Shares (Diluted)46.54M47.23M51.4M73.91M83.07M

Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Intrinsic Alpha fair value

Locked

Current Price

$9.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.